Kidney Cancer Drugs Market to Expand at a 6.60% CAGR from 2014 to 2020 due to Approval of Novel Molecules Globally A new Transparency Market Research report states that the global kidney cancer drugs market is predicted to expand at a CAGR of 6.60% from 2014 to 2020. The title of the report is “Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.” Renal cell carcinoma (RCC) is a common kind of renal or kidney cancer. Transitional cell carcinoma (TCC) is also a key type of kidney cancer, but is less prevalent amongst individuals as compared to RCC. Surgical procedures alone are sometimes not sufficient for the treatment of these cancers, particularly in cases where patients develop metastatic cancers. This is when additional treatment regimens are recommended and immunotherapies and targeted therapies come into play. Kidney cancer drugs are considered to increase the overall lifespan, particularly in patients having an advanced stage of metastatic tumors.
As mentioned in the report, the increasing occurrence of kidney cancer and the rising aging population globally are amongst the key factors stimulating the growth of the market for kidney cancer drugs. In addition, several novel molecules receiving approval globally is also a prime factor fuelling the market. On the other hand, the soaring prices of branded cancer drugs may restrain the growth of the market. In addition, the rising inclination of the consumers towards generic drug variants may also have a negative impact on the market’s development. In terms of drug, the market is segmented into Sutent (Sunitinib), Afinitor (Everolimus), Nexavar (Sorafenib), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Proleukin (Aldesleukin), and Torisel (Temsirolimus). Amongst these, on the basis of revenue, Sutent led the market in 2013 owing to Sutent being the majorly prescribed drug in the first-line treatment for kidney cancer. In addition, Sutent is also amongst the top studied drugs within its class for multiple indications, as it targets multiple receptor tyrosine kinases (RTKs). On the other hand, Votrient is predicted to emerge as a market leader by 2017 and is expected to surpass Sutent and all other competitors owing to its unique first-line penetration and low pricing. Votrient exhibited a whopping CAGR of more than 40% between 2012 and 2016.